Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fimmu.2020.580250 http://scihub22266oqcxt.onion/10.3389/fimmu.2020.580250 33178207!7597438!33178207     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Immunol 2020 ; 11 (ä): 580250 Nephropedia Template TP {{tp|p=33178207|t=2020. A Longitudinal Study of Immune Cells in Severe COVID-19 Patients |pdf=|usr=}}{{33178207}} gab.com Text A Longitudinal Study of Immune Cells in Severe COVID-19 Patients JO: Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33178207 #FOAvip Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2-specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR expression was below the 8,000 AB/C threshold defining acquired immunodepression. A "V" trend curve for lymphopenia, monocyte numbers, and HLA-DR expression was observed with a nadir between days 11 and 14 after symptoms' onset. Intermediate CD14(++)CD16(+) monocytes increased early with a reduction in classic CD14(++)CD16(-) monocytes. Polyfunctional SARS-Cov-2-specific CD4 T-cells were present and functional, whereas virus-specific CD8 T-cells were less frequent and not efficient. We report a temporal variation of both innate and adaptive immunity in severe COVID-19 patients, helpful in guiding therapeutic decisions (e.g. anti-inflammatory vs. immunostimulatory ones). We describe a defect in virus-specific CD8 T-cells, a potential biomarker of clinical severity. These combined data also provide helpful knowledge for vaccine design. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT04386395. Twit Text FOAVip A Longitudinal Study of Immune Cells in Severe COVID-19 Patients ????Front Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33178207 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33178207 #FOAvip English Wikipedia <ref>{{Cite pmid|33178207}}</ref> A Longitudinal Study of Immune Cells in Severe COVID-19 Patients #MMPMID33178207 Payen D; Cravat M; Maadadi H; Didelot C; Prosic L; Dupuis C; Losser MR; De Carvalho Bittencourt M Front Immunol 2020[]; 11 (ä): 580250 PMID33178207show ga Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2-specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR expression was below the 8,000 AB/C threshold defining acquired immunodepression. A "V" trend curve for lymphopenia, monocyte numbers, and HLA-DR expression was observed with a nadir between days 11 and 14 after symptoms' onset. Intermediate CD14(++)CD16(+) monocytes increased early with a reduction in classic CD14(++)CD16(-) monocytes. Polyfunctional SARS-Cov-2-specific CD4 T-cells were present and functional, whereas virus-specific CD8 T-cells were less frequent and not efficient. We report a temporal variation of both innate and adaptive immunity in severe COVID-19 patients, helpful in guiding therapeutic decisions (e.g. anti-inflammatory vs. immunostimulatory ones). We describe a defect in virus-specific CD8 T-cells, a potential biomarker of clinical severity. These combined data also provide helpful knowledge for vaccine design. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/, identifier NCT04386395. |*Severity of Illness Index[MESH] |Aged[MESH] |Biomarkers[MESH] |CD4-Positive T-Lymphocytes/*immunology[MESH] |CD8-Positive T-Lymphocytes/*immunology[MESH] |COVID-19/*immunology/virology[MESH] |Female[MESH] |GPI-Linked Proteins/metabolism[MESH] |HLA-DR Antigens/immunology[MESH] |Humans[MESH] |Immunity, Cellular[MESH] |Lipopolysaccharide Receptors/metabolism[MESH] |Longitudinal Studies[MESH] |Male[MESH] |Middle Aged[MESH] |Monocytes/*immunology[MESH] |Prospective Studies[MESH] |Receptors, IgG/metabolism[MESH]A Longitudinal Study of Immune Cells in Severe COVID-19 Patients (epmc).pdf DeepDyve Pubget Overpricing